Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohort

23ME-00610 - 23andMe

A. Naing1; A.R. Khaki2; S. Kummar3; M.N. Al-Hallak4; A.R. Abdul Razak5; A.N. Diep6; M. Schmidt6; D. Maslyar6; R. Vold6; C.C. Hwang6; D.M. Glatt6

Jul 25, 2024